{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T20:47:01Z","timestamp":1769633221710,"version":"3.49.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T00:00:00Z","timestamp":1496620800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1245\/s10434-017-5911-6","type":"journal-article","created":{"date-parts":[[2017,6,5]],"date-time":"2017-06-05T10:17:48Z","timestamp":1496657868000},"page":"2611-2616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy"],"prefix":"10.1245","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9550-7394","authenticated-orcid":false,"given":"Nicole K.","family":"Zern","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony J.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Aniss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Delbridge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Learoyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sywak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,5]]},"reference":[{"key":"5911_CR1","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2009;19:1167\u2013214.","journal-title":"Thyroid."},{"key":"5911_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1\u2013134.","journal-title":"Thyroid."},{"key":"5911_CR3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1530\/EJE-11-0466","volume":"165","author":"MG Castagna","year":"2011","unstructured":"Castagna MG, Maino F, Cipri C, Belardini V, Theodoropoulou A, Cevenini G, et al.. Delayed risk stratification to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. Eur J Endocrinol. 2011;165:441\u20136.","journal-title":"Eur J Endocrinol."},{"key":"5911_CR4","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.clon.2010.04.005","volume":"22","author":"H Tala","year":"2010","unstructured":"Tala H, Tuttle RM. Contemporary post surgical management of differentiated thyroid carcinoma. Clin Oncol. 2010;22:419\u201329.","journal-title":"Clin Oncol."},{"key":"5911_CR5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/EJE-13-0524","volume":"170","author":"MJ Jeon","year":"2014","unstructured":"Jeon MJ, Kim WG, Park WR, et al. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2014;170:23\u201330.","journal-title":"Eur J Endocrinol."},{"key":"5911_CR6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12020-014-0213-2","volume":"46","author":"RM Tuttle","year":"2014","unstructured":"Tuttle RM. Editorial: optimal management of a biochemical incomplete response to therapy in differentiated thyroid cancer: aggressive treatment or cautious observation? Endocrine. 2014;46:363\u20134.","journal-title":"Endocrine."},{"key":"5911_CR7","doi-asserted-by":"crossref","unstructured":"Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341\u20139.","DOI":"10.1089\/thy.2010.0178"},{"key":"5911_CR8","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2265.2012.04342.x","volume":"77","author":"F Vaisman","year":"2012","unstructured":"Vaisman F, Momesso D, Bulzico DA, et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin Endocrinol (Oxf). 2012;77:132\u20138.","journal-title":"Clin Endocrinol (Oxf)."},{"key":"5911_CR9","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1210\/jc.2002-021365","volume":"88","author":"E Baudin","year":"2003","unstructured":"Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab. 2003;88:1107\u201311.","journal-title":"J Clin Endocrinol Metab."},{"key":"5911_CR10","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MD.0b013e31826a9c71","volume":"91","author":"RP Tufano","year":"2012","unstructured":"Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine. 2012;91:274\u201386.","journal-title":"Medicine."},{"key":"5911_CR11","doi-asserted-by":"crossref","first-page":"3702","DOI":"10.1210\/jc.2013-1584","volume":"98","author":"C Li","year":"2013","unstructured":"Li C, Han PA, Lee KC, et al. Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers. Clin Endocrinol Metab. 2013;98:3702\u201312.","journal-title":"Clin Endocrinol Metab."},{"key":"5911_CR12","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1007\/s00268-016-3534-x","volume":"40","author":"S Fraser","year":"2016","unstructured":"Fraser S, Go C, Aniss A, et al. BRAF(V600E) Mutation is associated with decreased disease-free survival in papillary thyroid cancer. World J Surg. 2016;40:1618\u201324.","journal-title":"World J Surg."},{"issue":"6","key":"5911_CR13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1530\/ERC-12-0239","volume":"19","author":"M Bullock","year":"2012","unstructured":"Bullock M, O\u2019Neill C, Chou A, et al. Utilisation of a monoclonal antibody for BRAFV600E detection in papillary thyroid carcinoma. Endocr Relat Cancer. 2012;19(6):779\u201384.","journal-title":"Endocr Relat Cancer."},{"key":"5911_CR14","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1007\/s12020-013-0097-6","volume":"46","author":"P Fabian","year":"2014","unstructured":"Fabian P, Erika A, Hernan T, Fernanda B, Carolina U, Graciela C. Biochemical persistence in thyroid cancer: is there anything to worry about? Endocrine. 2014;46:532\u20137.","journal-title":"Endocrine."},{"key":"5911_CR15","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1089\/thy.2011.0522","volume":"22","author":"RP Padovani","year":"2012","unstructured":"Padovani RP, Robenshtok E, Brokhin M, Tuttle RM. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. 2012; 22:778\u201383.","journal-title":"Thyroid."},{"key":"5911_CR16","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.2013.3190","volume":"309","author":"M Xing","year":"2013","unstructured":"Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309:1493\u2013501.","journal-title":"JAMA."},{"key":"5911_CR17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.surg.2012.08.039","volume":"152","author":"JD Prescott","year":"2012","unstructured":"Prescott JD, Sadow PM, Hodin RA, et al. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. Surgery. 2012;152:984\u201390.","journal-title":"Surgery."},{"key":"5911_CR18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00268-013-2223-2","volume":"38","author":"Y Ito","year":"2014","unstructured":"Ito Y, Yoshida H, Kihara M, Kobayashi K, Miya A, Miyauchi A. BRAFV600E Mutation analysis in papillary thyroid carcinoma: is it useful for all patients? World J Surg. 2014;38:679\u201387.","journal-title":"World J Surg."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-017-5911-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5911-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-017-5911-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T10:39:46Z","timestamp":1501583986000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-017-5911-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,5]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["5911"],"URL":"https:\/\/doi.org\/10.1245\/s10434-017-5911-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,5]]}}}